Cargando…

Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity

Background. Preclinical data indicate that trabectedin followed by irinotecan has strong synergistic effects on Ewing sarcoma. This is presumably due to hypersensitization of the tumor cells to the camptothecin as an effect of trabectedin in addition to synergistic suppression of EWS-FLI1 downstream...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herzog, J., von Klot-Heydenfeldt, F., Jabar, S., Ranft, A., Rossig, C., Dirksen, U., Van den Brande, J., D'Incalci, M., von Luettichau, I., Grohar, P. J., Berdel, W. E., Burdach, St.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2016
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098094/ https://www.ncbi.nlm.nih.gov/pubmed/27843394 http://dx.doi.org/10.1155/2016/7461783

Ejemplares similares

Trabectedin and Plitidepsin: Drugs from the Sea that Strike the Tumor Microenvironment
por: Galmarini, Carlos M., et al.
Publicado: (2014)

Trabectedin, a drug acting on both cancer cells and the tumour microenvironment
por: D'Incalci, M, et al.
Publicado: (2014)

Trabectedin: A drug from the sea that strikes tumor-associated macrophages
por: Allavena, Paola, et al.
Publicado: (2013)

New activities for the anti-tumor agent trabectedin: taking two birds with one stone
por: D'Incalci, Maurizio, et al.
Publicado: (2013)

Editorial: Trabectedin, lurbinectedin, and other marine-derived anticancer alkaloids on solid cancer: Mechanisms of action, clinical impact, and future perspectives
por: Zambelli, Alberto, et al.
Publicado: (2023)

Effects of the Anti-Tumor Agents Trabectedin and Lurbinectedin on Immune Cells of the Tumor Microenvironment
por: Allavena, Paola, et al.
Publicado: (2022)

Trabectedin in Soft Tissue Sarcomas
por: Petek, Bradley J., et al.
Publicado: (2015)

Trabectedin for soft tissue sarcoma
Publicado: (2021)

Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin
por: Colmegna, B, et al.
Publicado: (2015)

Trabectedin modulates the senescence-associated secretory phenotype and promotes cell death in senescent tumor cells by targeting NF-κB
por: Camorani, Simona, et al.
Publicado: (2018)

Mechanism of action of trabectedin in desmoplastic small round cell tumor cells
por: Uboldi, S., et al.
Publicado: (2017)

Inhibition of tumor‐associated macrophages by trabectedin improves the antitumor adaptive immunity in response to anti‐PD‐1 therapy
por: Belgiovine, Cristina, et al.
Publicado: (2021)

The Role of Trabectedin in Soft Tissue Sarcoma
por: Nakamura, Tomoki, et al.
Publicado: (2022)

Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer
por: Jones, Robin L., et al.
Publicado: (2021)

Efficacy of Trabectedin in Patients with Advanced Translocation‐Related Sarcomas: Pooled Analysis of Two Phase II Studies
por: Takahashi, Mitsuru, et al.
Publicado: (2017)

A systems biology approach to investigate the mechanism of action of trabectedin in a model of myelomonocytic leukemia
por: Mannarino, L, et al.
Publicado: (2018)

Correlation of Transcriptomics and FDG-PET SUVmax Indicates Reciprocal Expression of Stemness-Related Transcription Factor and Neuropeptide Signaling Pathways in Glucose Metabolism of Ewing Sarcoma
por: Prexler, Carolin, et al.
Publicado: (2022)

Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms
por: Romano, Michela, et al.
Publicado: (2017)

Trabectedin: Safety and Efficacy in the Treatment of Advanced Sarcoma
por: Gajdos, Csaba, et al.
Publicado: (2011)

Role of trabectedin in the treatment of soft tissue sarcoma
por: Christinat, Alexandre, et al.
Publicado: (2009)

The value of trabectedin in the treatment of soft tissue sarcoma
por: Nakamura, Tomoki, et al.
Publicado: (2016)

A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin
por: Grosso, Federica, et al.
Publicado: (2012)

Relevance of Abnormal KCNN1 Expression and Osmotic Hypersensitivity in Ewing Sarcoma
por: Fuest, Sebastian, et al.
Publicado: (2022)

A Systems Biology Approach to Characterize the Regulatory Networks Leading to Trabectedin Resistance in an In Vitro Model of Myxoid Liposarcoma
por: Uboldi, Sarah, et al.
Publicado: (2012)

Trabectedin and its potential in the treatment of soft tissue sarcoma
por: Cassier, Philippe A, et al.
Publicado: (2008)

Trabectedin for advanced soft tissue sarcomas: optimizing use
por: Reid, Alison, et al.
Publicado: (2014)

Pharmacometabolomics of trabectedin in metastatic soft tissue sarcoma patients
por: Corona, Giuseppe, et al.
Publicado: (2023)

Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin
por: Bello, Ezia, et al.
Publicado: (2019)

Correction: Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin
por: Bello, Ezia, et al.
Publicado: (2020)

Effectiveness of irinotecan plus trabectedin on a desmoplastic small round cell tumor patient-derived xenograft
por: Zuco, Valentina, et al.
Publicado: (2023)

Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin
por: Desar, Ingrid M E, et al.
Publicado: (2016)

No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease
por: Thiel, U., et al.
Publicado: (2021)

Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age
por: HOICZYK, MATHIAS, et al.
Publicado: (2013)

The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
por: Ordóñez, José Luis, et al.
Publicado: (2015)

Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives
por: Gordon, Erlinda M., et al.
Publicado: (2016)

Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas
por: Recine, Federica, et al.
Publicado: (2017)

Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas
por: Laroche, Audrey, et al.
Publicado: (2017)

Radiosensitizing Effect of Trabectedin on Human Soft Tissue Sarcoma Cells
por: Loi, Mauro, et al.
Publicado: (2022)

Correction to: No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease
por: Thiel, U., et al.
Publicado: (2021)

HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance
por: Loria, Rossella, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0h8981enumpi7bgd0g6crflu6p